Abstract
Overview
Introduction
Datamonitor believes that companies developing pipeline drugs for the
depression market should concentrate resources on targeting third-line
depression patients, a market with significant sales volume and few viable
treatment options. GSK' s gepirone ER is likely to be the first pipeline drug
to enter the market and exploit this opportunity, with forecast sales of $615m
in 2016.
Scope
- Analysis of patient potential, unmet needs and clinical trial design in
depression
- Overview of drugs in late- and early-stage clinical development; with
analysis of key companies involved in the market
- Detailed profiles of key compounds in development for use in depression,
with forecasts of drug revenues to 2016
- Discussion of GSK' s and Sanofi-Aventis' strategies, and insight from key
industry opinion leaders
Report Highlights
Of the novel pipeline drugs in late-stage development for depression,
Datamonitor believes gepirone ER has the most revenue potential over the
forecast period. This will be the first pipeline drug to enter the market and
compete for market share with current third-line therapies, and has the
considerable marketing support of GSK.
Wyeth' s lifecycle management strategy of developing the Effexor reformulation
Pristiq, will not successfully maintain revenues for its depression franchise
following generic incursion of Effexor XR in 2010.
Agomelatine, a melatonin agonist and serotonin receptor ligand, will be a
valuable treatment option for mild/moderate MDD patients with prominent sleep
disorder co-morbidity or an add-on therapy for more severe MDD sufferers.
Reasons to Purchase
- Understand unmet needs in the depression market based on key opinion
leader comments
- Benchmark key late-stage depression compounds against current market
leaders
- Assess the global (US, Japan, five major EU) sales forecasts of key
late-stage pipeline drugs; and examine their clinical and commercial potential
View Cart
